ADVAIR HFA - (0.045MG;0.021MG, 0.115MG;0.021MG, 0.23MG;0.021MG)

Generic Name	FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE	**Innovator**	GlaxoSmithkline
Dosage	0.045MG;0.021MG, 0.115MG;0.021MG, 0.23MG;0.021MG	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	Less Than 5	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	ADVAIR HFA is indicated for the long-term, twice-daily maintenance treatment of asthma in patients 12 years of age and older.		
Complexities	Yes		

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.